PrEP is a once-daily medication used to prevent the development of HIV cases. It is intended for people who do not currently have HIV but have a higher risk of contracting the infection.
PrEP reduces your risk of developing HIV by protecting you and your partners from infection. It is not intended for people who are currently living with HIV.
Today, the FDA has approved two different antiviral medications for PrEP. They are highly effective at preventing HIV infection when taken regularly.
Please continue reading to learn more about PrEP medications and their role in reducing the risk of contracting HIV.
PrEP medications are classified as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). They work by inhibiting the virus's replication within your body.
Prior to initiating PrEP and at least every three months after that, you must be tested for HIV and negative results.
If you have been exposed to HIV or exhibit acute HIV symptoms, you will wait until you test negative before restarting your PrEP medication.
It is critical to wait for a negative test result because PrEP cannot treat HIV effectively on its own, and drug resistance may develop if PrEP is used during an HIV infection.
Counseling for prevention is another critical component of PrEP. Before initiating PrEP therapy, a healthcare professional can assist you in the following ways:
Your health factors will determine the duration of your PrEP treatment. Consult a healthcare provider about your health history and the time of your PrEP treatment.
Truvada and Descovy are the two approved PrEP medications.
Emtricitabine and tenofovir disoproxil fumarate are the active ingredients in Truvada. It is available as a brand-name medication as well as a generic medication.
Truvada is available in a variety of strengths and is prescribed for HIV treatment or pre-exposure prophylaxis.
It is available in tablet form and should be taken daily by adults and adolescents, weighing at least 35 kilograms (around 77 pounds). Truvada is safe and effective in both males and females.
Descovy is also a once-daily tablet. Emtricitabine and tenofovir alafenamide are the active ingredients.
Adults and adolescents weighing at least 35 kilograms may use Descovy (77 pounds). Descovy is not approved for use by females at a higher risk of contracting HIV through vaginal sex, as its effectiveness in this group has not been established.
According to the Centers for Disease Control and Prevention (CDC), 1.2 million people contracted HIV in the United States in 2018 — and one in seven people were unaware they had contracted the virus.
Individuals who have had anal or vaginal sex in the last six months and those who:
Additionally, it is recommended for individuals who inject drugs and:
If you have been prescribed post-exposure prophylaxis (PEP) multiple times and your risk of developing HIV continues to increase, speak with a healthcare professional about starting PrEP.
Numerous factors must be considered when initiating a new medication. Consider the following factors when determining whether PrEP is right for you:
When taken on a regular schedule as prescribed by a doctor, PrEP is highly effective at preventing HIV.
According to the CDC, when taken regularly, these medications reduce the risk of contracting HIV from sex by approximately 99 percent and by about 74% in people who inject drugs.
However, the medications listed above are not immediately effective. They must be taken daily for at least seven days to provide maximum protection against HIV transmission during receptive anal sex.
Maximum protection occurs after approximately 21 days of daily use of injection drugs or receptive vaginal sex.
Bear in mind that the efficacy of Descovy has not been established in females who have receptive vaginal sex.
Truvada and Descovy are generally considered to be safe, but some individuals may experience adverse effects. Several of these negative effects may be severe.
Consult a healthcare professional before initiating Descovy or Truvada for PrEP to discuss any health conditions you may have and the potential side effects and benefits of PrEP. For instance, if you have severe kidney disease, you may not take these medications.
Additionally, inform your doctor if you have ever had hepatitis B. Withdrawing from Truvada or Descovy may exacerbate a hepatitis B infection.
A healthcare professional will monitor your liver function and treat any recurrent hepatitis B infections.
It is critical to avoid PrEP medications if you have HIV. If you take the drug while living with HIV, the medicine may develop resistance to the virus.
You will undergo a blood test before beginning the medication and at least every three months while on it.
The following are some of the more common side effects of both medications:
Both have rare but severe side effects, including the following:
These are not all of the possible Truvada and Descovy side effects. Consult a healthcare professional or pharmacist for additional information about these medications, including possible interactions with other prescription or OTC medications you take.
If you have an allergic reaction or another severe side effect from PrEP medications, immediately call 911 or go to an emergency medical center.
If you believe you may have an increased risk of developing HIV, it is critical to discuss this with a trained healthcare professional and take steps to protect yourself from HIV.
Here are some suggestions for igniting a meaningful discussion:
If you believe you may be at risk of contracting HIV, it is critical to undergo routine testing and speak with a counselor or healthcare professional about possible prevention measures.
PrEP may be included as part of your prevention strategy. HIV PrEP is a highly effective medication regimen that can significantly reduce your risk of contracting HIV and transmitting it to sexual partners.
Consult a healthcare professional or schedule an appointment with a clinic that provides HIV prevention and health counseling.